ESSIC uses the name bladder pain syndrome (BPS) instead of interstitial cystitis (IC) and/or painful bladder syndrome (PBS): click here for more details.
A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Uçeyler N, Häuser W, Sommer C. Arthritis Rheum 2008;59:1279-98
• in this systematic review it is concluded that amitriptyline (25-50 mg/day) reduced pain, fatigue, and depressiveness in patients with fibromyalgia and improved sleep and quality of life • most SSRIs and the SNRIs duloxetine and milnacipran are probably also effective
• the authors recommend short-term treatment of patients with fibromyalgia using amitriptyline or another of the antidepressants that were effective in randomized-controlled trials but warn that data on long-term efficacy are lacking
The Fibromyalgia Bladder Index. Brand K, Littlejohn G, Kristjanson L, et al. Clin Rheumatol 2007;26:2097-103 • the aim of this study was to determine whether the Interstitial Cystitis Symptom and Problem Index (ICSI/ICPI), is a valid, reliable, and clinically relevant instrument to assess the sensory urinary symptoms in women with fibromyalgia syndrome (FM)
• factor analysis displayed two separate components of symptom and problem combinations as distinct from the original ICSI/ICPI developed for the interstitial cystitis population
• the eight items of the index configured differently and formed two subscales of a newly developed Fibromyalgia Bladder Index
• the two subscales of this index include the Bladder Urgency and Pain Subscale and the Bladder Frequency and Nocturia Subscale.
